EKF Diagnostics Holdings plc (AIM:EKF)

Market Cap	104.33M +17.3%
Revenue (ttm)	51.56M +2.7%
Net Income	2.12M -66.0%
EPS	0.00 -65.8%
Shares Out	431.10M
PE Ratio	51.49
Forward PE	15.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	107,388
Average Volume	551,307
Open	23.75
Previous Close	24.20
Day's Range	23.60 - 24.10
52-Week Range	19.00 - 32.00
Beta	0.53
RSI	37.44
Earnings Date	Mar 24, 2026

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Cl...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1990
• Employees: 297
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: EKF

Financial Performance

In 2025, EKF Diagnostics Holdings's revenue was 51.56 million, an increase of 2.73% compared to the previous year's 50.19 million. Earnings were 2.12 million, a decrease of -66.00%.